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The proportion of serum carnosinase (CN-1) recognized by RYSK173 monoclonal antibody
negatively correlates with CN-1 activity. We thus hypothesized that the epitope recognized
by RYSK173 is accessible only in a catalytically incompetent conformation of the zinc
dependent enzyme and we mapped its position in the CN-1 structure. Since patients with
kidney failure are often deficient in zinc and other trace elements we also assessed the
RYSK173 CN-1 proportion in serum of these patients and studied the influence of hemodial-
ysis hereon in relation to Zn2+ and Cu2+ concentration during hemodialysis.
Methods and Results
Epitope mapping using myc-tagged CN-1 fragments and overlapping peptides revealed
that the RYSK173 epitope directly contributes to the formation of the dinuclear Zn center in
the catalytic domain of homodimeric CN-1. Binding of RYSK173 to CN-1 was however not
influenced by addition of Zn2+ or Cu2+ to serum. In serum of healthy controls the proportion
of CN-1 recognized by RYSK173 was significantly lower compared to end-stage renal dis-
ease (ESRD) patients (1.12 ± 0.17 vs. 1.56 ± 0.40% of total CN-1; p<0.001). During hemodi-
alysis the relative proportion of RYSK173 CN-1 decreased in parallel with increased serum
Zn2+ and Cu2+ concentrations after dialysis.
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Conclusions
Our study clearly indicates that RYSK173 recognizes a sequence within the transition metal
binding site of CN-1, thus supporting our hypothesis that metal binding to CN-1 masks the
epitope. The CN-1 RYSK173 proportion appears overall increased in ESRD patients, yet it
decreases during hemodialysis possibly as a consequence of a relative increase in transi-
tion metal bound enzyme.
Introduction
Serum carnosinase (CN-1) (UniProt identifier Q96KN2) is abundantly expressed in the liver
from where it is secreted into the circulation [1]. Based on structural similarity, CN-1 has been
classified as metallopeptidase belonging to the M20 family of clan MH. CN-1 is composed of
two structural domains of which one adopts an α/ß/α sandwich fold that features a dinuclear
zinc-binding site [2]. The other, smaller domain is inserted into the middle of the metal-bind-
ing domain and, as in most M20 family enzymes, mediates homodimerization of CN-1. Two
active sites per dimer are located at the interface between one metal-binding domain and the
two associated dimerization domains, respectively. In CN-1 (MEROPS accession number
MER015142), H478 and E200 chelate zinc 1, and H132 and D228 chelate zinc 2. D165 acts as a
bridging ligand and the catalytic water molecule completes the tetrahedral coordination sphere
for both zinc ions. Mutation of H132, D165, or E200 would lead to the loss of CN-1 activity,
indicating the importance of metal-binding for enzyme activity [3]. Previously we have demon-
strated that serum CN-1 concentration and activity are genetically determined by the (CTG)n
polymorphism [4, 5] and by N-glycosylation of CN-1 [6]. In addition CN-1 hydrolytic activity
can be modulated by divalent metal ions, such as Cd2+, Co2+, Fe2+, Ni2+ [3], and by competing
substrates, such as anserine and homocarnosine [1, 7].
In the past years the CNDP1 gene, encoding CN-1, has attracted much attention as suscepti-
bility locus for diabetic nephropathy (DN) in type 2 diabetic patients [4, 8]. It is believed that
genotypes that are associated with low serum CN-1 concentrations may afford protection
against DN as a consequence of reduced carnosine degradation. Yet, it should be emphasized
that irrespective of the CNDP1 genotype carnosine concentrations are extremely low or unde-
tectable in human serum or plasma. Carnosine can be detected in serum only transiently after
oral carnosine supplementation in individuals with low serum CN-1 concentrations [9].
We have developed two ELISA assays for detection of human serum CN-1 [10]. Quantitative
assessment of serum CN-1 concentrations using the ATLASmonoclonal antibody based ELISA,
reveals a good correlation with CN-1 activity. The other ELISA is based on the so-called
RYSK173 monoclonal antibody and only detects a certain proportion of the total serum CN-1
concentration. The RYSK173 proportion can be increased by addition of EDTA or serum dena-
turation [10]. Hence the RYSK173 based ELISA assesses CN-1 quality rather than quantity.
While in the majority of individuals the proportion of total CN-1 that is recognized by RYSK173
is low (0.1 to 2%), we have reported that individuals with a high proportion of this conformation
(>15%) have low CN-1 activities [10]. Since metal ions at the active center of CN-1 are contrib-
uting to its enzyme activity, the proportion of CN-1 that is recognized by RYSK173 might be
partly lacking these ions. Because formal proof for the assumption that RYSK173 distinguishes
between apoenzyme and transition metal bound CN-1 is lacking, we sought to probe the posi-
tion of the RYSK173 epitope in relation to the metal binding site of CN-1.
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Methods and Materials
Generation of RYSK173 antibody
Monoclonal antibody RYSK173 was generated as described in [10]. In brief, Balb/c mice were
immunized by intraperitoneal injection of recombinant human CN-1. Three days after the last
boost splenocytes were collected and fused with SP2/0 myeloma cells. The fused cells were
seeded in 96-well plates (1×103 cells per well) and screened for anti-carnosinase antibody in
the supernatant by indirect immune fluorescence (IIF) on CN-1 transfected COS7 cells. Posi-
tive wells were sub-cloned by limiting dilution. Clone RYSK173 was selected on the basis of a
strong staining in IIF.
Cell culture and transfection
COS7 cells (Invitrogen, Karlsruhe, Germany) were cultured in Dulbecco´s modified Eagle´s
medium (DMEM/F-12, GlutaMAX(TM), Invitrogen, Karlsruhe, Germany) supplemented with
10% fetal calf serum (FCS) and 1% penicillin/streptomycin at 37°C and 5% CO2. The cells were
transfected with various length of CNDP1 constructs and lipofectamine2000 (Invitrogen,
Karlsruhe, Germany) according to the manufacture´s instruction. Five hours after transfection,
the medium was replaced by normal DMEMmedium. Supernatants and cell lysates were col-
lected after 48 hours. Cells were lysed on ice by lysis buffer with the addition of dithiothreitol
(Fluka Chemie GmbH, Buchs, Germany), protease inhibitor (Roche, Mannheim, Germany),
and phosphatase inhibitor (Sigma, Steinheim, Germany). Cell lysates were centrifuged for 10
minutes (14000rpm, at 4°C) to remove cell debris.
Human umbilical vein endothelial cells (HUVEC) were isolated from fresh human umbili-
cal cords as previously described [11]. The cells were cultured in endothelial cell growth
medium enriched with 2% FCS and 50ng/ml amphotericin B together with 50μg/ml gentami-
cin at 37°C and 5% CO2. The flasks for HUVECs were coated in 1% gelatin 20 minutes before
use. All experiments involving HUVECs were performed at passages 2–6. Umbilical cords
were obtained from donors in the obstetric department of Medical Center Mannheim. This
was also approved by local ethics committee (Medizinische Ethikkommission II der Medizi-
nischen Fakultät Mannheim) and all donors gave their written informed consent (No. 2015-
518N-MA).
Lentivirus production and transduction
Lentiviral transduction was performed to produce HUVECs with stable CN-1 expression.
Human CNDP1 cDNA (RZPD, Library 983, entry No.BX094414) was firstly constructed into
lentivirus based vector ppM337 which was kindly provided by Prof. P. Maier from Radiology
department of Medical Faculty Mannheim of Heidelberg University. In brief, each culture dish
was coated with 0.1mg/ml poly-D-lysine (Sigma, Steinheim, Germany) for 5 min and then
washed with sterile distilled water. 5×106 HEK293T/17 cells were seeded per dish in DMEM.
For each dish, 4.4μg lentiviral plasmid, 3.4μg packaging plasmid pCMV891 and 2.2μg pMD.G
were added to cells with 46μl metafectene (Biontex, Munich, Germany). Cell medium was
substituted by 14ml DMEM with 10mMNa-butyrate for 8 hours the next day. Lentiviruses
containing cell medium was collected and concentrated using Vivaspin20 (Sartorius stedim,
Göttingen, Germany) on the third day.
For transduction, HUVECs were incubated in 1:100 diluted virus containing HEK293T/17
supernatant for 48 hours. Cells were lysed either by lysis buffer or by a freeze and thaw cycle in
liquid nitrogen. Westernblotting of 20μg total protein from HUVECs supernatant and cell
lysates was performed to confirm the transduction.
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Construction of CNDP1 variants
CNDP1 cDNA was taken as a template to generate CNDP1 fragments by PCR. PCR amplifica-
tion was carried out from bp 1 to bp 312, from bp 1 to bp 471 and from bp 313 to bp 471 using
the following forward and reverse primers respectively:
1–312: cagcccatcgatatggatcccaaactcaggaga and agctttaaatcgatgatc
gggcagctgctgag




Amplification products were cloned into the pCSII + mt vector providing a N-terminal
6×myc-tag and subsequently transfected into COS7 cells as previously described.
Synthetic peptides
Three overlapping CN-1 peptides were synthesized (BIOMATIK, Wilmington, USA) that




Fine epitope mapping was subsequently performed using two peptides that covered the
overlapping sequence of CN1-2 and CN1-3, i.e. CN1-4 (HLDVQPAD) and CN1-5
(PADRGDGWL). All peptides were dissolved in sterile distilled water (final concentration:
10mg/ml) and were tested for recognition by RYSK173 by dotblot analysis and/or ELISA.
CN-1 detection
Both the RYSK173 and ATLAS based CN-1 ELISA assays were used for detection of CN-1 in
serum samples. CN-1 ELISAs were performed as described [10]. For epitope mapping synthetic
peptides were directly coated on the ELISA plates.
Gel electrophoresis and western blot were performed using a standard protocol. Dot blot
assays were performed by spotting 2 μl of synthetic peptide solution on a nitrocellulose mem-
brane. The membrane was dried and processed similar as has been described for westernblot-
ting [10].
Site mutagenesis
One nucleotide mutation in CN-1 was generated by the QuikChange™XL site-directed muta-
genesis kit (Stratagene, Waldbronn, Germany). H132 was exchanged to Q132. The forward





Thirty one patients on hemodialysis were recruited from our dialysis ward. They all had differ-
ent causes of end stage renal disease. Renal transplant recipients, patients with urinary tract
infection or fever at the time of investigation were excluded. Diabetic patients were also
excluded since diabetes per semight potentially influence CN-1 metabolism. Demographic and
relevant clinical data of these patients are shown in Table 1. Sera from age and gender matched
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healthy controls (n = 111) were retrieved from our bio-bank. The study was approved by local
ethics committee (Medizinische Ethikkommission II der Medizinischen Fakultät Mannheim)
and all patients gave their written informed consent prior to study (No. 0193/2001).
Trace metal analysis
Copper and zinc in serum were analysed at Laboratory Limbach (Heidelberg, Germany) by col-
orimetric photometry as described previously [12, 13]. Visibly hemolyzed serum samples were
not analysed.
Statistical analysis
Quantitative data are depicted as mean ± SD. Student t test (normal distribution) or Wilcoxon-
Mann-Whitney test (non-normal distribution) was used to compare differences between the
groups. Correlation between values was evaluated by Pearson correlation coefficients. Signifi-
cance was defined according to a p-value< 0.05. Statistical analysis was performed with
GraphPad Prism 6.0 (GraphPad Software, Inc, La Jolla, California).
Results
Epitope mapping of RYSK173
Since we have previously demonstrated that addition of EDTA improved CN-1 detection by
RYSK173 [10], we anticipated that the epitope on CN-1 which is recognized by RYSK173
resides within the metal-binding domain of CN-1. Because we also have shown that RYSK173
recognizes a CN-1 fragment when truncated before the first N-glycosylation site [6] we con-
structed three myc tagged CN-1 fragments that differed in size (Fig 1). While a myc-tagged
recombinant fragment of CN-1 spanning bp 1–471 was detected by both RYSK173 and myc
antibodies, a shorter fragment (bp 1–312) was only recognized by the myc antibody. Because a
recombinant CN-1 fragment corresponding to bp 313–471 was also recognized by both anti-
bodies our data suggest that the RYSK173 epitope resides within this part of the CN-1 protein
(Fig 1A, panel on the left). Three overlapping synthetic peptides of approximately 30 amino
acids that covered the 313–471 bp fragments were subsequently tested by dot blot analysis for
RYSK173 binding. CN1-2 and CN1-3 were clearly recognized whereas CN1-1 was not (Fig 1A,
panel on the right). To delineate the exact epitope on CN-1 that is recognized by RYSK173,
Table 1. Relevant clinical data of ESRD patients.
ESRD patients (n = 31)
Gender (male) 20 (65%)
Age (year) 55.0 ± 2.4
Plasma creatinine (mg / dl) 10.6 ± 0.58
[Zinc] before/after hemodialysis (μmol/L) 9.5 ± 0.2 / 10.9 ± 0.2 (p < 0.05)
[Copper] before/after hemodialysis (μg/L) 14.1 ± 0.4 / 15.3 ± 0.4 (p < 0.05)




Pyelonephritis or hydronephrosis 6
Polycysitic kidney disease 2
Others (non-diabetes) 4
doi:10.1371/journal.pone.0146831.t001
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Fig 1. Epitopemapping of RYSK173. A: Myc-tagged recombinant CN-1 fragments were expressed in COS7 cells by transfection. Cells were harvested and
the recombinant proteins were detected byWesternblotting using RYSK173 or anti-Myc (Fig on the left). Three overlapping synthetic peptides (CN1-1, CN1-
2 and CN1-3) corresponding to bp 313–471 were tested in dotblot analysis (Fig on the right). B: Two additional peptides (CN1-4 and CN1-5) corresponding to
the overlapping sequence of CN1-2 and CN1-3 were tested in ELISA for recognition by RYSK173. C: Location of the dinuclear zinc center at the CN-1
homodimer interface. The monomer on the left is depicted as a ribbon drawing and the monomer on the right is rendered as solid surface. Zinc1 and zinc2 in
the left monomer are shown as cyan and magenta colored spheres, respectively. The enlarged view details the position of the RYSK173 epitope, which is
confined to the amino acid sequence H132 to D139 (both marked with an asterisk). The surface of the left subunit is rendered semi-transparent. The Fig was
made with Protein Workshop. D: H132 was exchanged for glutamine (Q) by site directed mutagenesis. The recombinant proteins were detected in
transfected cell lysates using the ATLAS and RYSK173 based ELISA. The results are expressed as RYSK173/ATLAS ratio x 100%. NC: negative control,
WT: wild type.
doi:10.1371/journal.pone.0146831.g001
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two different peptides corresponding to the overlapping sequence of CN1-2 and CN1-3
(HLDVQPADRGDGWL) were tested by ELISA. The peptides CN1-4 (HLDVQPAD) and CN1-5
(PADRGDGWL) consisted of either the first 8 or last 9 amino acids of the overlapping peptide
sequence of CN1-2 and CN1-3 respectively. Synthetic peptides CN1-2, CN1-3 and CN1-4 were
all detected in ELISA by RYSK173 whereas CN1-1 and CN1-5 were not (Fig 1B). This demon-
strates that the RYSK173 epitope is contained in the sequence spanning the zinc 2-binding resi-
due H132 to D139. Inspection of its spatial position within the metal binding domain of CN-1
reveals its proximity to both metal ions and the homodimer interface (Fig 1C). We also demon-
strate that H132 is an integral constituent amino acid of the RYSK173 epitope, since site
directed mutation of H132 to Q132 in recombinant CN-1 (rCN-1) expressed in COS7 cells
resulted in a significant decrease in detection by RYSK173 (Fig 1D).
Recognition of serum CN-1 and recombinant expressed CN-1 in
HUVECs by RYSK173
Since our epitope mapping studies have demonstrated that epitope which is recognized by
RYSK173 directly contributes to the formation of the Zn dinuclear centres in CN-1, we studied
if CN-1 recognition by RYSK173 is changed once CN-1 is secreted. This would indicate that
loading of the Zn centres would occur extracellularly. To this end, we first assessed if ectopi-
cally expressed rCN-1 in supernatants and cell lysates of CN-1 transduced HUVECs is recog-
nized in the RYSK173- and ATLAS based ELISA, the latter recognizing total CN-1 [10]. While
in cell lysates of CNDP1 transfected HUVECs (n = 6) CN-1 was detected to a similar extent by
ATLAS and RYSK173, in supernatants only a fraction of total CN-1 was recognized by
RYSK173 (Fig 2A). Since the lysis buffer contained both EDTA and DTT, the difference in
RYSK173 recognition of CN-1 in cell lysates and supernatants is likely explained by denatur-
ation of the protein [10]. We therefore used freeze thaw cycles as a more gentle way to obtain
intra-cellular proteins (n = 6). Although the yield of CN-1 was significantly lower than the pre-
vious cell lyses method, similar as observed for serum (Fig 2B), CN-1 concentrations were sig-
nificantly higher in the ATLAS based as compared to the RYSK173 based CN-1 ELISA (Fig
2C), albeit that the difference was less pronounced as compared to serum.
We next tested if recovery of rCN-1 was impaired when spiked in human serum or FCS.
While the recovery of rCN-1 significantly decreased in human serum, detection of rCN-1 was
not significantly influenced in FCS (Fig 3A). Because the concentrations of the trace metal ions
Zn2+ and Cu2+ were different between the two types of serum (Zn2+ concentration: 11.7±0.1 vs.
18.7±0.1 μmol/L and Cu2+ concentration: 822±11.3 vs. 89.5±0.7 μg/L; human serum vs. FCS),
we tested if addition of ZnCl2 or CuSO4 influences the recovery of rCN-1 in the RYSK173
based ELISA. Neither addition of 100μMZnCl2 nor CuSO4 were able to reduce the recovery of
rCN-1 in PBS (Fig 3B) or in FCS (data not shown). Additionally, no significant differences
were found even if higher concentrations of metal ions were used (data not shown).
The relative proportion of CN-1 recognized by RYSK173 is increased in
ESRD patients
Recent evidence indicates that patients with kidney failure are often deficient in zinc and other
trace elements [14]. We therefore assessed to what extent end-stage renal disease (ESRD)
patients differ in the proportion of CN-1 that is recognized by RYSK173. As depicted in Fig
4A, the relative proportion of CN-1 that was recognized by RYSK173 was significantly higher
in ESRD patients as compared to healthy controls. The serum Zn2+ concentrations in ESRD
patients ranged from (6.8 to 12.1 μmol/L) while that of healthy controls were all in the normal
range (9.2 to 18.4 μmol/L). Since all ESRD patients were on hemodialysis, we also assessed the
RYSK173 Antibody Recognizes Zinc Center of CN-1
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Fig 2. Recognition of recombinant and serumCN-1 by RYSK173. A: recombinant CN-1 was expressed in HUVECs by lentiviral transduction. The
recombinant proteins were detected in cell lysates and supernatants using the ATLAS (filled bars) and RYSK173 (open bars) based ELISA. The results of 6
transduction experiments are depicted and expressed as mean CN-1 concentration (ng/ml) ± SD. B: Serum samples of 111 healthy individuals were tested in
the ATLAS and RYSK173 based ELISA. C: Cell disruption was performed by repeated freeze thawing. Similar as in serum RYSK173 detected significantly
lower amounts of CN-1.
doi:10.1371/journal.pone.0146831.g002
Fig 3. Recovery of recombinant CN-1 in serum. A: Equal amounts of recombinant CN-1 were spiked in PBS, human serum or FCS. While in human serum
detection of CN-1 by RYSK173 was strongly diminished this was not observed in FCS. B: The influence of ZnCl2 (100μM) and CuSO4 (100μM) on detection
of CN-1 by RYSK173 was tested. Ns: not significant.
doi:10.1371/journal.pone.0146831.g003
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influence of hemodialysis on serum CN-1 concentrations in parallel to changes in serum Zn2+
and Cu2+ concentrations. To this end, serum CN-1, measured by both RYSK173 and ATLAS
based ELISA, Zn2+ and Cu2+ concentrations were assessed directly before and after one hemo-
dialysis session. While total serum CN-1 concentrations were significantly increased in the
post-dialysis samples and correlated to the amount of ultrafiltration (Fig 4B), the proportion of
CN-1 recognized by RYSK173 was decreased in these samples (Fig 4C). Zinc and copper con-
centrations were expressed as percentage (%) change of Zn2+ and Cu2+ concentrations in the
post dialysis sample relative to the serum sample obtained directly before hemodialysis. In
approximately 5 out of 31 samples the Zn2+ and Cu2+ ion concentration did not change or
Fig 4. SerumCN-1 concentrations in ESRD patients. A: Sera of 31 ESRD patients were collected and tested in the ATLAS based and RYSK173 based
ELISA. Sera of 111 healthy individuals served as control. The results are expressed as RYSK173/ATLAS ratio x 100%. B: Serum was collected directly
before or after hemodialysis. The influence of hemodialysis on total CN-1 expression (B), the RYSK173 proportion (C) and changes in Zn2+ and Cu2+ (D)
concentrations were assessed. UF: ultrafiltration, BW: body weight, HD: hemodialysis, conc: concentration.
doi:10.1371/journal.pone.0146831.g004
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decreased over hemodialysis (Fig 4D, lower left quadrant), while in the majority of samples
either Zn2+, Cu2+ or both were increased after dialysis (Fig 4D).
Discussion
In the present study we sought to map the epitope that our anti-CN-1 monoclonal antibody
RYSK173 recognizes in CN-1. Our previous finding that chelators of transition metal ions
were able to unmask the epitope had led us to expect its location in the vicinity of the metal
binding site of CN-1. Our results unambiguously demonstrate that the epitope recognized by
RYSK173 indeed is in intimate contact with the dinuclear zinc site in CN-1 and even includes
metal ligand H132. Metalloproteases are ubiquitous enzymes able to degrade an array of pro-
tein substrates. Mostly these enzymes utilize conserved amino acid residues to generate a scaf-
fold capable of binding one or two metal ions [15]. Their functionality depends on subtle
interactions between the electronic properties of the metal ion, dictated by its coordination
chemistry, and the stability of protein conformations.
Previous mutational and structural analyses of CN-1 homologs from the M20 family have
suggested that these enzymes require both metal sites in their dinuclear zinc centers for optimal
protein stability but that zinc 1 is often bound with low affinity [16]. It may thus be easily
removed by EDTA, a treatment which we have formerly shown to partially improve CN-1 rec-
ognition by RYSK173 [10]. Immediate proximity of the epitope to both zinc sites in CN-1 (Fig
1) agrees with the notion that removal of zinc 1 leads to its exposure due to local protein
unfolding. The dinuclear zinc center in CN-1 is formed by H478 and E200 which coordinate
with zinc 1 and H132 and D228 coordinating with zinc 2. Site directed mutagenesis of H132 to
glutamine significantly impaired binding of RYSK173 indicating that this residue is part of the
RYSK173 epitope. It should be emphasized that binding of RYSK173 in the presence of EDTA
is still significantly lower compared to binding of the polyclonal antibody ATLAS. Only after
protein denaturation binding of RYSK173 to CN-1 equals that of ATLAS. This is in line with
our experimental data that no difference in CN-1 binding was observed between RYSK173 and
ATLAS in lysates of CNDP1 transduced HUVECs when a DTT and EDTA containing lysis
buffer was used.
In line with our previously published data [10], a large difference in CN-1 concentrations
are detected in human serum when using the ATLAS or RYSK173 based ELISA (Fig 2B)
respectively. This might be explained by the fact that in a fraction of CN-1 the Zn centers are
not completely occupied. To elucidate if Zn binding already occurs inside the cells shortly
before CN-1 is secreted, we performed ELISA on supernatants and cell lysates using the
RYSK173 antibody. Indeed we found a significant lower amount of CN-1 in the RYSK173- as
compared to the ATLAS based ELISA in cell lysates (p< 0.05, Fig 2C) that were obtained with-
out the use of denaturation or EDTA. This might indicate that zinc binding to CN-1 already
occurs intracellularly and still proceeds extracellularly as the difference between the RYSK173
and ATLAS based ELISA was much more pronounced in supernatants (p< 0.001, Fig 2A) as
compared to cell lysates. The ATLAS and RYSK173 based ELISA detected comparable CN-1
concentrations in cell lysates when the lysis buffer contained DTT and EDTA.
The finding that recovery of rCN-1 by the RYSK173 based ELISA was impaired in human
but not in fetal calf serum remains unexplained in our study. While Zn2+ concentrations were
slightly different in these two types of serum, the Cu2+ concentration in FCS was only 10% of
that found in human serum. Although it has been suggested for bovine lens leucyl aminopepti-
dases (blLAP) [17] and the aminoacylhistidine dipeptidase (PepD) [18, 19], that the zinc cen-
ters might be exchanged by other divalent cations with different exchange kinetics, to our
knowledge this has not been reported for CN-1. Addition of CuSO4 did not impair detection of
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rCN-1 in the RYSK173 based ELISA, suggesting that binding of Cu2+ to CN-1 in human serum
is unlikely a cause for the poor recovery by RYSK173.
Although our study does not provide direct evidence that divalent metal ion binding to CN-
1 masks the RYSK173 epitope, there seems to be a relation with trace metal ion concentrations
in serum. Firstly, we found a significant difference in the proportion of RYSK173 in serum of
patients with ESRD as compared to healthy controls. This was paralleled by a lower serum
Zn2+ concentration in ESRD patients. Secondly, the proportion of RYSK173 CN-1 was
decreased in the post-dialysis samples while in most patients the serum Zn2+ concentration
was increased directly after dialysis. Although the Cu2+ concentration increased in parallel in
the post-dialysis sample, direct binding of Cu2+ to the metal centres of CN-1 is highly unlikely.
A number of studies have suggested that CN-1 activity, either in serum or cerebrospinal
fluid, might be important in the pathology of chronic kidney disease [20], diabetic complica-
tions [4, 8, 21], Alzheimer’s disease [22, 23] or dementia [24]. CN-1 activity is not only depend-
ing on CN-1 concentrations but also on the presence of competing substrates [1] and the
relative proportion of CN-1 that is recognized by RYSK173 [10]. Although the RYSK173 is not
intended for implementation in routine diagnostics, it might help understanding why in some
patients CN-1 activity is extremely low despite the fact that CN-1 concentrations are normal.
In conclusion our study clearly indicates that RYSK173 recognizes a sequence within the
transition metal binding site of CN-1, thus supporting our hypothesis that metal binding to
CN-1 masks the epitope. The CN-1 RYSK173 proportion appears overall increased in ESRD
patients which might be explained by a relative Zn deficiency. It remains to be assessed if Zn
deficiency in general leads to an increase in the CN-1 RYSK173 proportion.
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